New Antibody Therapy for Residual Multiple Myeloma

In December 2025, interim results from a clinical trial have shown that the bispecific antibody linvoseltamab may eliminate residual traces of multiple myeloma, a deadly blood cancer.

Key Points

Potential Alternative to Bone Marrow Transplants: Researchers noted that patients typically undergo high-dose chemotherapy followed by a bone marrow transplant. Linvoseltamab could help many avoid this intensive process while improving long-term outcomes.
High Efficacy After Modern Upfront Therapy: Participants had already received effective frontline treatment that removed around 90% of their tumour burden. Linvoseltamab successfully targeted remaining cancer cells.
Nature of the Disease: Multiple myeloma arises from malignant plasma cells that accumulate in the bone marrow, disrupting normal blood cell production and causing organ damage. The disease currently has no established cure.
Side Effects and Safety: Some participants experienced expected side effects, including neutropenia and upper respiratory infections, but all were within acceptable safety limits.